Treatment of patients with chronic lymphocytic leukemia
The invention provides methods for treating a patient with chronic lymphocytic leukemia of B cells (B-CLL). One method comprises administering to a patient with B-CLL, one or more benzamide derivatives, the benzamide derivatives including MS-275 and related compounds. Another method comprises administering to a patient with B-CLL, one or more of the benzamide derivatives, and additionally administering to the patient one or more antibodies immunospecific for 1D10 antigen. Additional methods for inducing apoptosis of B-CLL cells and for increasing expression of 1D10 antigen in B-CLL cells using the benzamide derivatives are also provided.
1. A method for inducing apoptosis of B-CLL cells in a patient with B-CLL, comprising contacting the B-CLL cells with one or more anti-CLL agents, said agents comprising a benzamide derivative represented by the formula (I):
wherein A represents a structure shown by either of the formulas II, III or IV:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the anti-CLL agent is represented by the formula (V):
3. The method of claim 1 wherein the anti-CLL agent is represented by the formula (VI):
4. The method of claim 1 wherein the anti-CLL agent is represented by the formula (VII):
5. A method for increasing expression of 1D10 antigen in B-CLL cells in a patient with B-CLL, comprising contacting the B-CLL cells with one or more benzamide derivatives represented by the formula (I):
wherein A represents a structure shown by either of the formulas II, III or IV:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 wherein the benzamide derivative is represented by the formula (V):
7. The method of claim 5 wherein the benzamide derivative is represented by the formula (VI):
8. The method of claim 5 wherein the benzamide derivative is represented by the formula (VII):